EMA: 5 product-specific guidances adopted [BE/BA News]

posted by Helmut Homepage – Vienna, Austria, 2018-08-03 16:52 (848 d 02:09 ago) – Posting: # 19133
Views: 3,064

Dear all,

today the EMA published another set of product-specific guidances (adopted by the CHMP 26 July, effective with 2 February 2019):
  1. Agomelatine tablet 25 mg
  2. Posaconazole gastro-resistant tablet 100 mg
  3. Ledipasvir/sofosbuvir film-coated tablet 90 mg/400 mg
  4. Cholic acid capsules 50 mg and 250 mg
  5. Vismodegib hard capsule 150 mg

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,216 posts in 4,427 threads, 1,482 registered users;
online 21 (0 registered, 21 guests [including 15 identified bots]).
Forum time: Saturday 18:02 CET (Europe/Vienna)

Science may be described as the art of systematic over-simplification –
the art of discerning what we may with advantage omit.    Karl R. Popper

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5